ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2666

Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease

Danica Lee1, Urekha Karri2, Yiming Luo3, Kader Cetin Gedik4, Manuel Carpio Tumba5, Prabal Chhibbar6, Priyamvada Roy6, Guido Falduto7, Jishnu Das5 and Daniella Schwartz5, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2School of public health, Pittsburgh, PA, 3Columbia University, New York, NY, 4UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA, 6University of Pittsburgh School of Medicine, Pittsburgh, 7University of Pittsburgh Medical Center, Pittsburgh, PA

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Bioinformatics, Demographics, genetics, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)

Session Type: Abstract Session

Session Time: 12:15PM-12:30PM

Background/Purpose: TNFAIP3 encodes the ubiquitin editing enzyme A20, which inhibits multiple proinflammatory signaling pathways. Heterozygous germline mutations in TNFAIP3 cause the autoinflammatory disease Haploinsufficiency of A20 (HA20). The prevalence of HA20 is thought to be low, with only 200 reported cases, yet HA20 is clinically heterogeneous and has variable severity. The full spectrum of disease-causing and disease-modifying TNFAIP3 variants is unknown. Therefore, we hypothesized that HA20 prevalence is underestimated due to ascertainment bias.

Methods: To better understand HA20 prevalence and ascertain its full phenotypic spectrum, we analyzed three large population databases with whole genome sequencing data: gnomad v4 (730,947 exomes; 76,215 genomes), All of Us v7 (244,845 genomes and electronic health records (EHR) data), and UK BioBank (500,000 genomes and EHR data). We identified individuals harboring rare (MAF< 0.01%) predicted loss-of-function (pLOF) variants (frameshift, truncating, splice null) or rare predicted pathogenic missense (pPM) variants (CADD≥30; SIFT=deleterious; PolyPhen=probably damaging). Phenome-wide association studies (PheWAS) determined conditions that were significantly associated with pLOFs and pPMs. We then functionally validated the variants by performing luciferase assays to measure TNF-induced NF-kB activation, Western blot to measure basal A20 expression, and cycloheximide assays to measure protein stability. Lastly, we compared our results from these “virtual” cohorts to a “referral” cohort of patients seen at our medical center who harbor LOF (48 subjects, 17 variants) or missense (14 subjects, 9 variants) TNFAIP3 mutations.

Results: pLOF variants had a mean prevalence of 1:14,403, while pPM variants had a mean prevalence of 1:2,782, suggesting that ~100,000 to 2.9 million individuals worldwide may suffer from A20-insufficient disease. TNFAIP3 variants conferred a 164-fold risk of Behcet’s disease and a 14-fold to 138-fold risk of other HA20-associated phenotypes like stomatitis/mucositis, vasculitis, and autoimmune hemolytic anemia (PheWAS, p < 1e-5, Bonferroni). In vitro, variants reduced A20 stability, expression, and/or TNF-induced NF-kB activation. In our Pittsburgh cohort, patients exhibited clinical autoinflammation and/or autoimmunity as well as evidence of basally activated TNF-NFκB, inflammasome-IL-1β, and/or Type I interferon signaling. LOF and missense variants either increased A20 protein degradation, resulted in production of an A20 protein unable to suppress TNF-induced NFkB activation, or reduced both protein stability and function. Patients exhibited >90% response to therapies targeting A20-regulated pathways such as TNF, IL-1, and JAK inhibitors.

Conclusion: Together, these data suggest that hypomorphic TNFAIP3 variants are a massively underrecognized cause of autoinflammation with high disease burden. Increased recognition and expanded genetic testing could potentially improve health outcomes by directing these patients towards more precise immune-targeting therapies.

Supporting image 1Table 1. Prevalence estimates of pLOF or missense TNFAIP3 variants in the US (AoU), UK (UKBB), and globally (gnomAD). Number of individuals harboring pLOF variants, or pPM variants (missense variants with CADD³30; SIFT=deleterious; PolyPhen=probably damaging; MAF < 0.01%). Mean prevalence of the variants and affected number of individuals were estimated based on the 2024 U.S. Census count of 340.1 million. 

Supporting image 2Figure 1. Inflammatory conditions are significantly associated with pathogenic TNFAIP3 variants. Manhattan plot of conditions that are significantly associated with rare pathogenic TNFAIP3 variants in meta-PheWAS of AoU and UKBB data. Each data point represents one condition. Blue line represents uncorrected p-value and red line represents Bonferroni adjusted p-value. The table above reports odds ratio (OR) for top associated conditions compared to control cohort.

Supporting image 3Figure 2. Hypomorphic TNFAIP3 variants can affect A20 function and/or expression. (A) Over-expressed mutant A20 proteins fail to suppress TNF-induced NF-kB activity in A20-deficient HEK293 cells transfected with the luciferase reporter plasmid (*p < 0.05, ratio paired t-test); WT = wild-type, EV = empty vector. (B) Basal A20 expression (Western blot) of A20 variants, expression normalized to actin.


Disclosures: D. Lee: None; U. Karri: None; Y. Luo: None; K. Cetin Gedik: None; M. Carpio Tumba: None; P. Chhibbar: None; P. Roy: None; G. Falduto: None; J. Das: None; D. Schwartz: Eli Lilly, 5, Jeffrey Modell Foundation, 5, National Institutes of Health, 5, Samuel and Emma Winters Foundation, 5, Sobi, 1, 5.

To cite this abstract in AMA style:

Lee D, Karri U, Luo Y, Cetin Gedik K, Carpio Tumba M, Chhibbar P, Roy P, Falduto G, Das J, Schwartz D. Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/rare-tnfaip3-hypomorphic-variants-are-a-massively-underestimated-driver-of-human-autoinflammatory-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rare-tnfaip3-hypomorphic-variants-are-a-massively-underestimated-driver-of-human-autoinflammatory-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology